A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Monoterapia rytuksymabem w pęcherzycy liściastej
Introduction. Rituximab is a chimeric human-mouse monoclonal antibody,which binds to the CD20 antigen on B and pre-B lymphocytesand causes depletion of CD20+ cells in the mechanism of complement-dependent and independent cytolysis, antibody-dependent cell cytotoxicityand the mechanism of apoptosis. Rituximab is currently registeredfor the treatment of non-Hodgkin's lymphoma, chronic lymphocyticleukaemia and rheumatoid arthritis. Rituximab has alsodemonstrated efficacy in a number of otherdoaj:cdf9fff4eb254b97a29eafd79c1fce82 fatcat:jpp26czpa5fijcva4a73vzebwm